project id: TCGA-MESO; case submitter id: TCGA-3U-A98D; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.34; rna integrity number: 7.1; age at index: 80; days to birth: -29500; days to death: 142; ethnicity: not reported; gender: male; race: white; vital status: Dead; year of birth: 1932; age at diagnosis: 29500; ajcc pathologic m: M0; ajcc pathologic n: N2; ajcc pathologic stage: Stage III; ajcc pathologic t: T2; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 125.0; icd 10 code: C45.0; last known disease status: not reported; morphology: 9053/3; primary diagnosis: Mesothelioma, biphasic, malignant; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Pleura, NOS; synchronous malignancy: No; tissue or organ of origin: Pleura, NOS; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 628; days to sample procurement: 0; initial weight: 230.0; portion submitter id: TCGA-3U-A98D-01A-12; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 80.0;